Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NYSE:NBY NASDAQ:NERV NASDAQ:PRPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.57+14.3%$2.73$7.96▼$24.15$23.05M0.6315,685 shs10.82 million shsNBYNovaBay Pharmaceuticals$4.22+57.5%$0.90$0.44▼$4.44$24.58M0.62.51 million shs19.48 million shsNERVMinerva Neurosciences$2.31-3.8%$2.00$1.15▼$3.00N/A-0.2540,893 shs9,747 shsPRPHProPhase Labs$0.36-0.7%$0.37$0.22▼$3.00$14.91M-0.7815.32 million shs3.02 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+14.25%+48.38%+69.89%+46.95%-73.65%NBYNovaBay Pharmaceuticals+57.46%+155.76%+590.67%+627.59%+795.97%NERVMinerva Neurosciences-3.75%-3.91%+25.54%+26.30%-11.83%PRPHProPhase Labs-0.72%+2.86%+15.86%-0.45%-86.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.57+14.3%$2.73$7.96▼$24.15$23.05M0.6315,685 shs10.82 million shsNBYNovaBay Pharmaceuticals$4.22+57.5%$0.90$0.44▼$4.44$24.58M0.62.51 million shs19.48 million shsNERVMinerva Neurosciences$2.31-3.8%$2.00$1.15▼$3.00N/A-0.2540,893 shs9,747 shsPRPHProPhase Labs$0.36-0.7%$0.37$0.22▼$3.00$14.91M-0.7815.32 million shs3.02 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+14.25%+48.38%+69.89%+46.95%-73.65%NBYNovaBay Pharmaceuticals+57.46%+155.76%+590.67%+627.59%+795.97%NERVMinerva Neurosciences-3.75%-3.91%+25.54%+26.30%-11.83%PRPHProPhase Labs-0.72%+2.86%+15.86%-0.45%-86.24%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ANBYNovaBay Pharmaceuticals$9.78M2.51N/AN/A$4.25 per share0.99NERVMinerva NeurosciencesN/AN/A$0.20 per share11.48($3.67) per shareN/APRPHProPhase Labs$6.77M2.19N/AN/A$0.25 per share1.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%11/10/2025 (Estimated)NBYNovaBay Pharmaceuticals-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/ANERVMinerva Neurosciences$1.44M$1.481.56N/AN/AN/A-41.35%31.37%11/4/2025 (Estimated)PRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-262.42%-76.48%11/12/2025 (Estimated)Latest NBY, NERV, ALVR, and PRPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025NERVMinerva Neurosciences-$0.95-$0.43+$0.52-$0.43N/AN/A8/13/2025Q2 2025PRPHProPhase Labs-$0.15-$0.11+$0.04-$0.11$3.55 million$1.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/ANBYNovaBay PharmaceuticalsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78NBYNovaBay PharmaceuticalsN/A1.150.91NERVMinerva NeurosciencesN/A6.156.15PRPHProPhase Labs0.200.960.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%NBYNovaBay Pharmaceuticals23.25%NERVMinerva Neurosciences34.56%PRPHProPhase Labs9.45%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%NBYNovaBay Pharmaceuticals0.10%NERVMinerva Neurosciences8.60%PRPHProPhase Labs9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableNBYNovaBay Pharmaceuticals305.82 million4.88 millionNot OptionableNERVMinerva Neurosciences9N/AN/ANot OptionablePRPHProPhase Labs13041.54 million37.55 millionOptionableNBY, NERV, ALVR, and PRPH HeadlinesRecent News About These CompaniesProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025September 3 at 6:34 PM | markets.businessinsider.comProPhase Labs Inc. to Participate in Renmark's Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025September 3 at 8:00 AM | globenewswire.comProPhase Labs, Inc. (PRPH) Q2 2025 Earnings Call TranscriptAugust 20, 2025 | seekingalpha.comProPhase Labs files definitive proxy statement for special meetingAugust 20, 2025 | msn.comProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of ShareholdersAugust 19, 2025 | globenewswire.comProPhase Labs Inc (PRPH) Q2 2025 Earnings Call Highlights: Strategic Moves and Future ProspectsAugust 15, 2025 | finance.yahoo.comProPhase Labs Reports Turnaround and Strategic GrowthAugust 14, 2025 | msn.comProPhase Labs Posts Narrower Q2 LossAugust 13, 2025 | aol.comAProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025August 13, 2025 | globenewswire.comProPhase Labs stock soars after securing patent for esophageal disease testAugust 12, 2025 | investing.comEarnings Preview For ProPhase LabsAugust 12, 2025 | benzinga.comProPhase Labs Shares Surge 38% Following Patent Approval for Esophageal Disease TestAugust 12, 2025 | msn.comWhy Is ProPhase Labs Stock (PRPH) Up 25% Today?August 12, 2025 | msn.comProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk AssessmentAugust 12, 2025 | globenewswire.comProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025August 11, 2025 | globenewswire.comProPhase Labs Appoints New Fractional CFOAugust 6, 2025 | tipranks.comProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy StatementJuly 29, 2025 | globenewswire.comProPhase Labs announces closing of $3M senior secured convertible notesJuly 25, 2025 | msn.comProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes FinancingJuly 23, 2025 | globenewswire.comProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury InitiativeJuly 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBY, NERV, ALVR, and PRPH Company DescriptionsAlloVir NASDAQ:ALVR$4.57 +0.57 (+14.25%) As of 09/3/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.NovaBay Pharmaceuticals NYSE:NBY$4.22 +1.54 (+57.46%) As of 09/4/2025 04:00 PM EasternNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Minerva Neurosciences NASDAQ:NERV$2.31 -0.09 (-3.75%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$2.38 +0.06 (+2.81%) As of 09/4/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.ProPhase Labs NASDAQ:PRPH$0.36 0.00 (-0.72%) Closing price 09/4/2025 03:59 PM EasternExtended Trading$0.36 +0.01 (+1.57%) As of 09/4/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
